Personalize treatment selection when starting, switching, or stopping a pharmacologic based on efficacy, safety, and patient preference
Personalize treatment selection when starting, switching, or stopping a pharmacologic based on efficacy, safety, and patient preference Strongly agree
Personalize treatment selection when starting, switching, or stopping a pharmacologic based on efficacy, safety, and patient preference Agree
Personalize treatment selection when starting, switching, or stopping a pharmacologic based on efficacy, safety, and patient preference Neutral
Personalize treatment selection when starting, switching, or stopping a pharmacologic based on efficacy, safety, and patient preference Disagree
Personalize treatment selection when starting, switching, or stopping a pharmacologic based on efficacy, safety, and patient preference Strongly disagree
Evaluate the latest data on the efficacy, safety, and dosing/administration of currently approved DMTs to develop optimal individualized treatment strategies for patients with MS
Evaluate the latest data on the efficacy, safety, and dosing/administration of currently approved DMTs to develop optimal individualized treatment strategies for patients with MS Strongly agree
Evaluate the latest data on the efficacy, safety, and dosing/administration of currently approved DMTs to develop optimal individualized treatment strategies for patients with MS Agree
Evaluate the latest data on the efficacy, safety, and dosing/administration of currently approved DMTs to develop optimal individualized treatment strategies for patients with MS Neutral
Evaluate the latest data on the efficacy, safety, and dosing/administration of currently approved DMTs to develop optimal individualized treatment strategies for patients with MS Disagree
Evaluate the latest data on the efficacy, safety, and dosing/administration of currently approved DMTs to develop optimal individualized treatment strategies for patients with MS Strongly disagree